DB:82P

Stock Analysis Report

Executive Summary

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Pacira BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.8%

DB:82P

1.9%

DE Pharmaceuticals

0.8%

DE Market


1 Year Return

-15.3%

DB:82P

-10.6%

DE Pharmaceuticals

-10.9%

DE Market

82P underperformed the Pharmaceuticals industry which returned -10.7% over the past year.

82P underperformed the Market in Germany which returned -10.9% over the past year.


Share holder returns

82PIndustryMarket
7 Day-2.8%1.9%0.8%
30 Day-10.6%5.8%-5.0%
90 Day-13.9%12.7%-2.9%
1 Year-15.3%-15.3%-7.5%-10.6%-8.1%-10.9%
3 Year-2.2%-2.2%-10.8%-18.4%10.4%0.9%
5 Year-59.6%-59.6%31.5%9.9%25.5%8.1%

Price Volatility Vs. Market

How volatile is Pacira BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Pacira BioSciences undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Pacira BioSciences's share price is below the future cash flow value, and at a moderate discount (> 20%).

Pacira BioSciences's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Pacira BioSciences is overvalued based on earnings compared to the DE Pharmaceuticals industry average.

Pacira BioSciences is overvalued based on earnings compared to the Germany market.


Price Based on Expected Growth

Pacira BioSciences is poor value based on expected growth next year.


Price Based on Value of Assets

Pacira BioSciences is overvalued based on assets compared to the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Pacira BioSciences expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

44.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Pacira BioSciences's revenue is expected to grow by 10.1% yearly, however this is not considered high growth (20% yearly).

Pacira BioSciences's earnings are expected to grow significantly at over 20% yearly.

Pacira BioSciences's revenue growth is expected to exceed the Germany market average.

Pacira BioSciences's earnings growth is expected to exceed the Germany market average.

Pacira BioSciences's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Pacira BioSciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Pacira BioSciences performed over the past 5 years?

4.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Pacira BioSciences's year on year earnings growth rate has been positive over the past 5 years.

Pacira BioSciences has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Pacira BioSciences has become profitable in the last year making it difficult to compare the DE Pharmaceuticals industry average.


Return on Equity

Pacira BioSciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Pacira BioSciences used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Pacira BioSciences has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

  • Explore strong past performing companies in the Pharmaceuticals & Biotech industry.

Financial Health

How is Pacira BioSciences's financial position?


Financial Position Analysis

Pacira BioSciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Pacira BioSciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Pacira BioSciences's level of debt (87.3%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (68.8% vs 87.3% today).

Debt is well covered by operating cash flow (21.5%, greater than 20% of total debt).

Interest payments on debt are not well covered by earnings (EBIT is 1.8x annual interest expense, ideally 3x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.3x debt.


Next Steps

Dividend

What is Pacira BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Pacira BioSciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Pacira BioSciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Pacira BioSciences has not reported any payouts.

Unable to verify if Pacira BioSciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Pacira BioSciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Pacira BioSciences's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Dave Stack (69yo)

11.8yrs

Tenure

US$5,835,918

Compensation

Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira Pharmaceutical ...


CEO Compensation Analysis

Dave's remuneration is higher than average for companies of similar size in Germany.

Dave's compensation has increased in line with Pacira BioSciences recently becoming profitable.


Management Age and Tenure

3.3yrs

Average Tenure

53yo

Average Age

The tenure for the Pacira BioSciences management team is about average.


Board Age and Tenure

6.2yrs

Average Tenure

61yo

Average Age

The tenure for the Pacira BioSciences board of directors is about average.


Insider Trading

Pacira BioSciences individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$18,168,86705 Aug 19
Consonance Capital Management LP
EntityCompany
Shares449,827
Max PriceUS$40.39
SellUS$14,392,67210 Jul 19
Consonance Capital Management LP
EntityCompany
Shares361,656
Max PriceUS$39.80
SellUS$83,21912 Jun 19
Lauren Riker
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer & VP of Finance
Shares2,126
Max PriceUS$39.14
SellUS$27,56406 Jun 19
Roy Winston
EntityIndividual
Shares722
Max PriceUS$38.18
SellUS$96,55006 Jun 19
Kristen Dunker
EntityIndividual
Shares2,529
Max PriceUS$38.18
SellUS$472,82206 Jun 19
David Stack
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares12,385
Max PriceUS$38.18
SellUS$79,17906 Jun 19
Richard Scranton
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares2,074
Max PriceUS$38.18
SellUS$36,91706 Jun 19
Lauren Riker
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer & VP of Finance
Shares967
Max PriceUS$38.18
SellUS$42,22406 Jun 19
Charles Reinhart
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,106
Max PriceUS$38.18
SellUS$41,95706 Jun 19
Dennis McLoughlin
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,099
Max PriceUS$38.18
SellUS$16,41606 Jun 19
Charles Laranjeira
EntityIndividual
Role
Chief Technology Officer
Chief Technical Officer
Shares430
Max PriceUS$38.18
SellUS$18,130,08205 Jun 19
Consonance Capital Management LP
EntityCompany
Shares446,615
Max PriceUS$40.59
BuyUS$58,53308 Mar 19
Mark Kronenfeld
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,700
Max PriceUS$34.58
SellUS$599,31214 Dec 18
HBM Partners Ltd.
EntityCompany
Shares14,527
Max PriceUS$42.13
SellUS$40,69121 Nov 18
HBM Partners Ltd.
EntityCompany
Shares990
Max PriceUS$41.10
BuyUS$181,43921 Nov 18
Gary Pace
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,500
Max PriceUS$40.32
SellUS$2,926,73020 Nov 18
HBM Partners Ltd.
EntityCompany
Shares70,498
Max PriceUS$41.78
SellUS$242,67915 Nov 18
HBM Partners Ltd.
EntityCompany
Shares5,478
Max PriceUS$44.30
SellUS$2,625,19914 Nov 18
HBM Partners Ltd.
EntityCompany
Shares58,245
Max PriceUS$45.08
BuyUS$178,81709 Nov 18
Gary Pace
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,000
Max PriceUS$44.70
SellUS$3,231,08522 Oct 18
Consonance Capital Management LP
EntityCompany
Shares81,700
Max PriceUS$40.30
BuyUS$38,07630 Aug 18
Mark Kronenfeld
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$38.08

Ownership Breakdown


Management Team

  • Charlie Reinhart (58yo)

    Chief Financial Officer

    • Tenure: 3.3yrs
    • Compensation: US$1.41m
  • Dave Stack (69yo)

    Chairman & CEO

    • Tenure: 11.8yrs
    • Compensation: US$5.84m
  • Rich Scranton (52yo)

    Chief Medical Officer

    • Tenure: 1.0yrs
    • Compensation: US$2.27m
  • Charles Laranjeira (53yo)

    Chief Technical Officer

    • Tenure: 0.7yrs
  • Lauren Riker (40yo)

    Principal Accounting Officer & VP of Finance

    • Tenure: 7.4yrs
    • Compensation: US$288.82k
  • Max Reinhardt

    President

    • Tenure: 0.2yrs
  • Kristen Williams (45yo)

    Chief Administrative Officer & Secretary

    • Tenure: 4.8yrs
    • Compensation: US$1.94m
  • Richard Kahr

    Vice President of Human Resources

    • Tenure: 4.1yrs
  • Susan Mesco

    Head of Investor Relations

    • Tenure: 0.0yrs
  • Dennis McLoughlin (53yo)

    Chief Commercial Officer

    • Tenure: 1.0yrs
    • Compensation: US$2.53m

Board Members

  • Laura Brege (61yo)

    Independent Director

    • Tenure: 8.2yrs
    • Compensation: US$205.42k
  • Dave Stack (69yo)

    Chairman & CEO

    • Tenure: 11.8yrs
    • Compensation: US$5.84m
  • Paul Hastings (59yo)

    Lead Director

    • Tenure: 6.2yrs
    • Compensation: US$218.42k
  • Gary Pace (71yo)

    Director

    • Tenure: 11.2yrs
    • Compensation: US$180.22k
  • Andreas Wicki (61yo)

    Director

    • Tenure: 12.7yrs
  • John Longenecker (59yo)

    Director

    • Tenure: 12.1yrs
    • Compensation: US$202.42k
  • Mark Kronenfeld (64yo)

    Independent Director

    • Tenure: 6.2yrs
    • Compensation: US$190.42k
  • Yvonne Greenstreet (56yo)

    Director

    • Tenure: 5.4yrs
    • Compensation: US$184.42k
  • Mark Froimson (58yo)

    Director

    • Tenure: 2.2yrs
    • Compensation: US$175.42k

Company Information

Pacira BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pacira BioSciences, Inc.
  • Ticker: 82P
  • Exchange: DB
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.521b
  • Listing Market Cap: US$1.366b
  • Shares outstanding: 41.64m
  • Website: https://www.pacira.com

Number of Employees


Location

  • Pacira BioSciences, Inc.
  • 5 Sylvan Way
  • Suite 300
  • Parsippany
  • New Jersey
  • 7054
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2011
82PDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2011

Biography

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 21:42
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.